Molecular modification of a recombinant anti-CD3ε-directed immunotoxin by inducing terminal cysteine bridging enhances anti-GVHD efficacy and reduces organ toxicity in a lethal murine model

Blood

Volumn 96, Issue 3, 2000, Pages 1157-1165

  Vallera, D A ^a   Kuroki, D W ^a   Panoskaltsis Mortari, A ^a   Buchsbaum, D J ^a   Rogers, B E ^a   Blazar, B R ^a  

^a Mayo Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; DIPHTHERIA TOXIN; IMMUNOTOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISULFIDE BOND; DRUG ACTIVITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG TOLERANCE; GRAFT VERSUS HOST REACTION; HYBRIDOMA; LYMPHOCYTE PROLIFERATION; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TOXIN ANALYSIS;

EID: 0034254244     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.3.1157.015k56_1157_1165     Document Type: Article

References (59)

1. What can be done to prevent graft versus host disease?
2. Graft-versus-host-disease
3. Targeting T-cells for GVHD therapy
4. In vivo or in vitro anti-CD3 chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice
5. Effects of in vivo administration of anti-CD3 monoclonal antibody on T-cell function in mice: In vivo activation of T-cells
6. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients
7. Non-mitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft- versus-host disease induced across the major histocompatibility barrier
8. Mammalian expression and secretion of functional single-chain Fv molecules
9. Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in E coli
10. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49
11. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms
12. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erb B-2 single-chain Fv
13. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell
14. Immunotoxins: An update
15. Targeted therapy of cancer with recombinant immunotoxins
16. Clinical trials of targeted toxins
17. Anti-graft-versus-host disease effect of DT390-anti-CD3sFv, a single chain Fv fusion immunotoxin specifically targeting the CD3 epsilon moiety of the T-cell receptor
18. Therapy of ongoing graft-versus-host-disease (GVHD) induced across the major or minor histocompatibility barrier in mice with anti-CD3F(abi)2-RTA (ricin toxin A chain) immunotoxin
19. Human T lymphocyte differentiation antigens as target for immunotoxins or complement-mediated cytotoxicity
20. Toxicity and efficacy of anti-T-cell ricin toxin A chain immunotoxins in a murine model of established graft-versus-host disease induced across the major histocompatibility barrier
21. Cloned fragment of diphtheria toxin linked to T-cell-specific antibody identifies regions of B chain active in cell entry
22. Structure-activity relationships in diphtheria toxin and Pseudomonas aeruginosa exotoxin A
23. Renal dysfunction accounts for the dose limiting toxicity of DT390 anti-CD3sFv, a potential new recombinant anti-GVHD immunotoxin
24. Prolongation of cardiac allograft survival in murine recipients treated with a diphtheria toxin-related interleukin-2 fusion protein
25. Interleukin 4 receptor targeted cytotoxicity: Genetic construction and in vivo immunosuppressive activity of a diphtheria toxin-related murine interleukin 4 fusion protein
26. High level E.coli expression and production of a bivalent humanized antibody fragment
27. Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2
28. Engineering Fab' fragments for efficient F(ab')2 formation in E.coli and for improved in vivo stability
29. Comparative stabilities in vitro and in vivo of a recombinant mouse antibody FvCys fragment and a bisFvCys conjugate
30. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
31. A murine cytokine fusion toxin specifically targeting the murine granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor on normal committed bone marrow progenitor cells and GM-CSF dependent tumor cells
32. Identification of a monoclonal antibody specific for a murine T3 polypeptide
33. Monoclonal antibodies against the antigen receptor on a cloned T-cell hybrid
34. Characterization of the murine T-cell surface molecule, designated L3T4, to the human Leu-3/T4 molecule
35. T-cell subsets defined expression Lyt-1,2,3 and Thy-1 antigens
36. Characterization of a monoclonal antibody which detects murine alpha beta T-cell receptors
37. Successful treatment of human acute T-cell leukemia in SCID mice using anti-CD7-deglycosylated ricin a-chain immunotoxin DA7
38. Isolation of pure lgG1, lgG2a, and lgG2b immunoglobulins from mouse serum using protein A-sepharose
39. In vivo administration of anti-CD3 monoclonal antibodies or immunotoxins in murine recipients of allogeneic T-cell depleted marrow for the promotion of engraftment
40. Characterization of monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors
41. + T-cells each can utilize a perforin-dependent pathway to mediate lethal GVHD in MHC disparate
42. Lethal murine graft-versus-host-disease induced by donor gamma/delta expressing T cells with specificity for host nonclassical major histocompatibility complex lb antigens
43. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures
44. A method for the radio-halogenation of proteins resulting in decreased thyroid uptake of radioiodine
45. Evaluation of survival data in two new rank order statistics arising in its consideration
46. An engineered bivalent single-chain antibody fragment that increases antigen binding activity
47. Formation of a bispecific antibody by the use of leucine zippers
48. Miniantibodies: Use of amphipathic helices to produce functional, flexibly linked dimeric Fv fragments with high avidity in E coli
49. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts
50. Recombinant single-chain Fv fragments carrying c-terminal cysteine residues: Production of bivalent and biotinylated miniantibodies
51. Pharmacokinetics and antitumor activity of a bivalent disulfide- stabilized Fv immunotoxin with improved antigen binding to erbB2
52. Evaluation of ricin A-chain immunotoxins directed against human T- cells
53. Human Tlymphocyte differentiation antigens as target for immunotoxins or complement-mediated cytotoxicity
54. Antigenic modulation and toxicity of intact ricin immunotoxins directed against human T-cells
55. Evaluation of a CD5-specific immunotoxin for treatment of acute graft- versus-host disease after allogeneic marrow transplantation
56. The use of an anti-CD3 immunotoxin to prevent the development of lymphoproliferative disease in SCID/PBL mice
57. In vivo T-cell ablation by a holo-immunotoxin directed at human CD3
58. Treatment of acute graft-versus-host disease with a nonmitogenic anti- CD3 monoclonal antibody
59. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease